CSF2 and neoplasm: Clinical evaluation of the thymidine kinase-deficient Wyeth strain vaccinia vector (JX-594/Pexa-Vec) engineered to co-express GM-CSF demonstrated tumor-selective replication patterns in phase II sarcoma trials.